Work

Markers of inflammation as predictors of efficacy of trastuzumab therapy in HER2-positive metastatic breast cancer patients

Year: 2025

Type: article

Abstract: Inflammatory indexes correlate with the effectiveness of therapy and prognosis of many cancer types. Our study aimed to identify independent predictors of the efficacy of trastuzumab therapy affecting progression-free survival (PFS) and overall survival (OS) in patients with HER2-positive metastatic breast cancer (mBC). The retrospective study included 78 HER2-positive mBC patients treated with trastuzumab at Sumy Regional Clinical Oncology Center. The baseline clin i copathological characteristics including age, number of metastases, menopausal status, hormonal status, trastuzumab-containing regimen, and inflammatory indexes, such as neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), platelet to lymphocyte ratio (PLR) and pan-immune-inflammation value (PIV) , were collected. Cut-off values of inflammatory markers were determined by ROC analysis. AUC ≥0.7 was considered statistically significant. Factors affecting PFS and OS were determined using the multivariate Cox proportional hazard model. Response to treatment was assessed every 2-3 cycles. Low PLR and trastuzumab plus chemotherapy regimen correlated with a high disease control rate. Multivariate analysis assessed the prognostic impact of age, number of metastases, menopausal status, hormonal st a tus, trastuzumab-containing regimen, and inflammatory indexes on PFS and OS in HER2-positive mBC patients. Trast u zumab-containing regimen and PLR were independent predictors of PFS. Patients who received trastuzumab plus chem o therapy and whose PLR before treatment was low had significantly better PFS. For OS, multivariate analysis showed the same results. Low PLR and trastuzumab plus chemotherapy regimen were independent predictors of OS. Low PLR is associated with better PFS, OS, and a high disease control rate. PLR may be an effective marker for identifying the cand i dates who most benefit from trastuzumab. Compared with trastuzumab monotherapy, the combination of trastuzumab and chemotherapy correlates with longer PFS and OS in patients with HER2-positive mBC.

Source: Regulatory Mechanisms in Biosystems

DOI: 10.15421/0225003

Authors: O. Vynnychenko, Y. Moskalenko, R. Moskalenko

Institution: Sumy State University

Language: English

Topic: Inflammatory Biomarkers in Disease Prognosis

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $100